RS
XERS icon

R Squared’s Xeris Biopharma Holdings XERS Stock Holding History

R Squared’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,802
Closed -$80.1K – 709
2026
Q1 		$80.1K Buy
+13,802
New +$91.5K 0.04% 385
2025
Q4 		– Sell
-12,709
Closed -$103K – 741
2025
Q3 		$103K Buy
+12,709
New +$84.4K 0.04% 441
2025
Q2 		– Sell
-15,730
Closed -$86.4K – 574
2025
Q1 		$86.4K Buy
15,730
+3,410
+28% +$13.8K 0.09% 235
2024
Q4 		$41.8K Buy
+12,320
New +$39.6K 0.04% 570

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

R Squared's XERS Position: Q2 2026 in Review

R Squared sold out of Xeris Biopharma Holdings (XERS) in Q2 2026, closing a stake of 13,802 shares — an estimated $80.1K sold.

R Squared first reported a position in XERS in Q4 2024 and held it in 4 quarters. The position peaked at $103K in Q3 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • R Squared reported no remaining Xeris Biopharma Holdings position as of Q2 2026 after selling out during the quarter.
  • R Squared sold 13,802 Xeris Biopharma Holdings shares in Q2 2026, an estimated $80.1K.
  • R Squared first reported a position in Xeris Biopharma Holdings in Q4 2024 and held it in 4 quarters.
  • R Squared's Xeris Biopharma Holdings position peaked at $103K in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.